Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against CytRx Corporation and Reminds Investors With Losses to Contact the Firm

LADX

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit Against CytRx Corporation and Reminds Investors With Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that a class action lawsuit was filed against CytRx Corporation (“CytRx” or the “Company”) (Nasdaq: CYTR). Investors who purchased or otherwise acquired shares between November 18, 2014 and July 11, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the September 23, 2016 lead plaintiff motion deadline.

If you purchased shares of CytRx during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made materially false and misleading statements and/or failed to disclose that: the clinical hold placed on the Phase 3 trial of aldoxorubicin would prevent sufficient follow-up for patients involved in the study; that almost half of the patients would be excluded from the progression free survival evaluation; CytRx would like conduct a second analysis; that the results of the trial could be affected or approval of aldoxorubicin could be delayed; and that as a result of the above, the Company’s statements were false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today